Jun 4, 2026, 15:53
Rituximab and Eculizumab in Refractory Antiphospholipid Syndrome – APS Foundation of America
APS Foundation of America shared a post on LinkedIn:
“Rituximab and Eculizumab Show Benefit in Refractory Antiphospholipid Syndrome
Key Point: Across biologic therapies for antiphospholipid syndrome APS), rituximab and eculizumab had the most robust data, while belimumab and daratumumab were promising but supported by very limited early evidence.
‘Ultimately, personalized strategies integrating clinical phenotype, serology, and pathogenic mechanisms may offer the best approach for optimizing care in patients with refractory or complex APS.'”
Read More.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Sep 18, 2026, 20:27Hrishikesh Pai: Rethinking Male Infertility
-
Sep 18, 2026, 20:25Eric Verdin: Wrapping Up the Reproductive Aging Summit at the Center for Healthy Aging in Women
-
Sep 18, 2026, 20:21Investigating Pregnancy Outcomes in Women with Idiopathic POI – RBMO
-
Sep 18, 2026, 20:18Sue Ritchie: Why Aren’t We Talking About Male Fertility More?
-
Sep 18, 2026, 20:13Salma Yasin: Every Day of BFS Study Week 2026 Has Been an Exceptional Learning Experience
-
Sep 18, 2026, 20:01Qingcai Wang: Over 35 and Torn Between Trying Longer and Starting IVF?
-
Sep 18, 2026, 19:58Bhumika: Can a Woman Become Pregnant Again While Already Pregnant?
-
Sep 18, 2026, 19:5215 More Experts Join the International Fertility Forum Mumbai 2026
-
Sep 18, 2026, 19:50Curious About What Happens Behind the Scenes in the Labs? – Sims IVF